Alternative Data for Arcus Biosciences
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 24 | Sign up | Sign up | Sign up |
| Sentiment | 84 | Sign up | Sign up | Sign up |
| Webpage traffic | 8,000 | Sign up | Sign up | Sign up |
| Employee Rating | 68 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 2 | Sign up | Sign up | Sign up |
| Facebook Followers | 116 | Sign up | Sign up | Sign up |
| Instagram Followers | 135 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 24 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,803 | Sign up | Sign up | Sign up |
| Twitter Followers | 511 | Sign up | Sign up | Sign up |
| Twitter Mentions | N/A | Sign up | Sign up | Sign up |
| X Mentions | 26 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 56 | Sign up | Sign up | Sign up |
| Linkedin Employees | 675 | Sign up | Sign up | Sign up |
About Arcus Biosciences
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.
| Price | $21.53 |
| Target Price | Sign up |
| Volume | 7,420,000 |
| Market Cap | $3.11B |
| Year Range | $6.87 - $26.1 |
| Dividend Yield | 0% |
| Analyst Rating | 80% buy |
| Industry | Biotechnology |
In the news
HC Wainwright & Co. Maintains Arcus Biosciences (RCUS) Buy RecommendationDecember 12 - Fintel |
|
 |
Arcus Biosciences, Inc. (RCUS) Presents at Citi Annual Global Healthcare Conference 2025 TranscriptDecember 2 - SeekingAlpha |
B of A Securities Maintains Arcus Biosciences (RCUS) Neutral RecommendationNovember 28 - Fintel |
|
 |
Arcus Biosciences, Inc. (NYSE:RCUS) Just Reported Earnings, And Analysts Cut Their Target PriceNovember 1 - Yahoo |
 |
Arcus Biosciences 13.7M share Spot Secondary priced at $18.25October 31 - Thefly.com |
|
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common StockOctober 30 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 26M | 2M | 24M | -135M | -130M | -1.270 |
| Q2 '25 | 160M | 2M | 160M | -8M | 4M | 0.000 |
| Q1 '25 | 28M | 0 | 28M | -112M | -108M | -1.140 |
| Q4 '24 | 26M | 3M | 26M | -94M | -89M | -1.030 |
| Q3 '24 | 48M | 0 | 48M | -92M | -89M | -1.000 |
Insider Transactions View All
| Jaen Juan C. filed to sell 954,063 shares at $24.7. December 5 '25 |
| Goeltz II Robert C. filed to sell 87,138 shares at $25. November 26 '25 |
| Azoy Alexander filed to sell 27,363 shares at $26. December 1 '25 |
| Jaen Juan C. filed to sell 1,037,060 shares at $19.8. November 19 '25 |
| Jaen Juan C. filed to sell 1,042,110 shares at $20.7. November 19 '25 |
Similar companies
Read more about Arcus Biosciences (RCUS) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Arcus Biosciences?
The Market Cap of Arcus Biosciences is $3.11B.
What is the current stock price of Arcus Biosciences?
Currently, the price of one share of Arcus Biosciences stock is $21.53.
How can I analyze the RCUS stock price chart for investment decisions?
The RCUS stock price chart above provides a comprehensive visual representation of Arcus Biosciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Arcus Biosciences shares. Our platform offers an up-to-date RCUS stock price chart, along with technical data analysis and alternative data insights.
Does RCUS offer dividends to its shareholders?
As of our latest update, Arcus Biosciences (RCUS) does not offer dividends to its shareholders. Investors interested in Arcus Biosciences should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Arcus Biosciences?
Some of the similar stocks of Arcus Biosciences are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.
